Huaduo Biologics Completes D+1 Financing Round and Advances Three CAR-T Therapies into Clinical Trials

Feb 24, 2024 12:14 CST Updated 12:14

Huadao Biopharma

Developer and Manufacturer of Cell-Based Immunotherapy Drugs

Recently, HuaDao CAR-Tcell held a company-wide mobilization meeting for the 2024 work objectives.Chairman and General Manager of HuaDao CAR-Tcell, Yu Xuejun, inThe company announced the successful completion of its D+1 round of financing as scheduled and officially launched its D+2 round of financing.

HuaDao CAR-Tcell (Shanghai) Biopharmaceutical Co., Ltd. (referred to as HuaDao Biologics or the Company) is a biopharmaceutical enterprise specializing in cellular immunotherapy, with a particular focus on the technical development and innovation of the entire cell drug industry chain. Established in September 2017 in Zhangjiang, Shanghai, the company relocated to Songjiang, Shanghai in 2020, within the National Songjiang Economic and Technological Development Zone, the main hub of "Songjiang Creation."

In 2023, the company successively obtained clinical trial permits (IND) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration for three Class 1 new CAR-T drugs. The three CAR-T products are:

With the mission of "making cell drugs affordable for the Chinese people," the company adheres to a dual innovation path across the entire industrial chain, focusing on "cell drug R&D + key equipment and technology breakthroughs for industrialization" with independent intellectual property rights. After six years of development, the company has overcome key production equipment for CAR-T cell preparation,配套一次性耗材, intelligent CAR-T liquid nitrogen cold chain transport, and other critical CAR-T industrialization equipment and bottleneck technologies. It has become a national high-tech enterprise in China's cellular immunotherapy field, owning independent intellectual property rights for key equipment, reagents, and consumables across the entire industrial chain, as well as control over the pricing of CAR-T cell drugs.

In 2023, HuaDao CAR-Tcell fully launched the construction of six major industrial bases across China (East China Shanghai Songjiang Base (Phase I already in use, Phase II soon to be occupied), Southwest Chongqing Bishan Base, Northwest Shaanxi Xianyang Base, Northeast Jilin Changchun Base, Central Plains Henan Zhengzhou Base, South China Guangdong Guangzhou Base), committed to becoming a platform-based pharmaceutical enterprise with independent research and development and production transformation capabilities for cell drugs in China.

E.N.D

Previous article recommendations:

The First AAV Gene Drug Using a Two-Plasmid Packaging System: Goldwalk’s Leading Pipeline IND Approved

Gracell Biotechnologies Announces Official Merger into AstraZeneca Group

Shenyan Biotech Raises Over 300 Million RMB to Accelerate CGT Global Expansion

The Death of Jesse Gelsinger

Xiong'an Officially Issues! Support for the Development of Modern Life Sciences and Biotechnology Industries such as Cell Therapy, Genetic Engineering, and Tissue Engineering

Competitive Landscape of TIL Cell Therapy in China

Neurophth Announces Completion of Patient Enrollment in the U.S. Phase I/II Clinical Trial of AAV Gene Therapy NFS-01 (Trade Name: NuVigia®)

Market Value Exceeds $1.5 Billion: A Cell Therapy Company Successfully Goes Public in an IPO

The World's First TIL Therapy Approved for Marketing

Government Invests 6 Billion Yuan to Fund the Establishment of a Life Health Research Institute, Focusing on Cutting-edge Topics such as Cell and Gene Therapy

NVIDIA CEO Jensen Huang: The Era of Having to Learn Computer Science and Programming is Over, the Next Golden Track is Life Science and Engineering

EU Commission Approves First Gene-Editing Therapy for Market Launch

AstraZeneca Invests $300 Million to Build Cell Therapy Factory

China's First Universal CAR-NK for Treating Systemic Lupus Erythematosus Approved for Clinical Trials

World's First AAV Gene Therapy for Autism Approved for Clinical Trials

Beijing to Focus on Cell and Gene Therapy, Synthetic Biology Manufacturing as Key Tasks for 2024

Leading CDMO Company Discloses Nearly 100 Million Yuan Fraud Process

Bi Jingquan: Should Study Removing Cell Therapy and Gene Therapy from the Negative List for Foreign Investment

FDA Releases Guidelines for the Development of Gene-Editing Therapies and CAR-T Therapies (Full Text of Guidelines Attached)

Overview of U.S. Biomedical Sanctions Against China

Hengrui Medicine Subsidiary Files for First Gene Therapy Product

CDE Releases "Non-Clinical Research Technical Guiding Principles for Human Stem Cell Products"

CRISPR/Cas9 Gene Editing Therapy Receives FDA Approval for Treating β-Thalassemia

Disclaimer: The content is sourced from HuaDao CAR-Tcell. The purpose of this article is for knowledge sharing. All content is for reference only and does not constitute any advice.